Study guide

9.1 PALS Resuscitation Algorithms & Cardiac Arrest Pharmacotherapy

Board Certified Pediatric Pharmacy Specialist BCPPS

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Pediatric Patient Characteristics — Growth, Anthropometrics & Perinatal Exposure

1.1 Normal Growth, Development & Growth-Chart Interpretation 1.2 Anthropometrics: Body Surface Area, Dosing Weights & Maximum-Dose Caps 1.3 Medication Use in Pregnancy and Lactation

2 Chapter 2: Developmental Pharmacokinetics & Neonatal Principles

2.1 Developmental PK: Absorption, Distribution & Body Water Dynamics 2.2 Hepatic Metabolism & CYP/UGT Isoenzyme Maturation 2.3 Renal Function Maturation & Glomerular Filtration Development

3 Chapter 3: Neonatal Critical Care & Prematurity Complications

3.1 Neonatal Sepsis & Meningitis (Early-Onset vs Late-Onset Sepsis) 3.2 Respiratory Distress Syndrome, Surfactant & Bronchopulmonary Dysplasia 3.3 Patent Ductus Arteriosus, Apnea of Prematurity & Necrotizing Enterocolitis

4 Chapter 4: Pediatric Infectious Diseases — Respiratory & ENT Infections

4.1 Acute Otitis Media, Sinusitis & Pharyngitis 4.2 Pediatric Community-Acquired Pneumonia & Parapneumonic Effusion 4.3 Bronchiolitis, RSV Prevention (Nirsevimab, Clesrovimab, Palivizumab) & Viral Lower Respiratory Infections

5 Chapter 5: Pediatric Infectious Diseases — Systemic, Bone & CNS Infections

5.1 Pediatric Meningitis, Encephalitis & Brain Abscess 5.2 Skin, Soft Tissue, Osteomyelitis & Septic Arthritis 5.3 Pediatric Sepsis, Febrile Neutropenia & Central Line-Associated Bloodstream Infections

6 Chapter 6: Pediatric Pulmonary Medicine — Asthma & Status Asthmaticus

6.1 Chronic Pediatric Asthma Assessment & Stepwise Outpatient Pharmacotherapy 6.2 Status Asthmaticus & Acute Exacerbation Pharmacotherapy in ED/PICU 6.3 Aerosol Drug Delivery, Spacers & Specialized Inhalation Devices

7 Chapter 7: Cystic Fibrosis & Chronic Pediatric Respiratory Disorders

7.1 Pathophysiology, Diagnosis & Airway Clearance in Cystic Fibrosis 7.2 CFTR Modulator Therapies & Monitoring 7.3 CF Pulmonary Exacerbations, Chronic Infection Management & Comorbidities

8 Chapter 8: Pediatric Cardiology & Hemodynamics

8.1 Congenital Heart Defects & Ductal-Dependent Lesions 8.2 Pediatric Heart Failure & Cardiomyopathies 8.3 Pediatric Arrhythmias & Syncope Management

9 Chapter 9: Pediatric Resuscitation, Shock & Critical Care Support

9.1 PALS Resuscitation Algorithms & Cardiac Arrest Pharmacotherapy 9.2 Pediatric Shock States & Vasoactive / Inotropic Selection 9.3 Extracorporeal Membrane Oxygenation (ECMO) & Critical Care PK

10 Chapter 10: Pediatric Neurology & Psychiatric Disorders

10.1 Neonatal Seizures & Pediatric Status Epilepticus 10.2 Pediatric Epilepsy Syndromes & Maintenance Anticonvulsants 10.3 Attention-Deficit/Hyperactivity Disorder (ADHD) & Pediatric Mood Disorders

11 Chapter 11: Pediatric Endocrinology & Metabolic Disorders

11.1 Pediatric Type 1 Diabetes Mellitus Management & Insulin Technologies 11.2 Diabetic Ketoacidosis (DKA) Protocols & Cerebral Edema Prevention 11.3 Growth Hormone, Pubertal Disorders & Congenital Adrenal Hyperplasia

12 Chapter 12: Pediatric Hematology, Oncology & Supportive Care

12.1 Sickle Cell Disease: Vaso-occlusive Crises & Disease-Modifying Therapies 12.2 Pediatric Acute Lymphoblastic Leukemia (ALL) & Chemotherapy Toxicities 12.3 Oncologic Emergencies: Tumor Lysis Syndrome & Supportive Care

13 Chapter 13: Pediatric Medication Safety & Error Prevention

13.1 High-Alert Pediatric Medications & Ten-Fold Dosing Calculation Traps 13.2 Smart Infusion Pumps & Dose Error Reduction Systems (DERS) 13.3 Medication Reconciliation & Pediatric Care Transitions

14 Chapter 14: Pediatric Compounding & Formulation Technology

14.1 Non-Sterile Compounding (USP <795>) & Liquid Formulations 14.2 Sterile Compounding (USP <797>) & Micro-Dosing Considerations 14.3 Hazardous Drug Handling (USP <800>) & Excipient Toxicities

15 Chapter 15: Fluids, Electrolytes & Clinical Nutrition Support

15.1 Fluid Requirements, Dehydration Assessment & Maintenance Therapy 15.2 Electrolyte Disturbances: Sodium, Potassium & Calcium Management 15.3 Pediatric & Neonatal Parenteral Nutrition (PN) Formulation

16 Chapter 16: Pediatric Pain Management, Sedation & Delirium

16.1 Age-Specific Pain Assessment Tools & Analgesic Selection 16.2 Procedural Sedation & Rapid Sequence Intubation in Children 16.3 PICU Delirium, Iatrogenic Withdrawal & Weaning Strategies

17 Chapter 17: Biostatistics & Study Design in Pediatric Research

17.1 Observational vs Experimental Pediatric Study Designs 17.2 Biostatistical Testing, Power & Sample Size in Small Pediatric Cohorts 17.3 Diagnostic Testing, Sensitivity, Specificity & Predictive Values

18 Chapter 18: Pediatric Evidence Appraisal, Regulatory Framework & Ethics

18.1 Pediatric Drug Legislation: BPCA, PREA & Labeling Nuances 18.2 Institutional Review Boards (IRB), Assent & Informed Consent in Minors 18.3 Evaluating Clinical Practice Guidelines & Formulating Off-Label Recommendations

19 Chapter 19: Pediatric Education, Health Literacy & Communication

19.1 Caregiver Health Literacy & Pediatric Medication Adherence 19.2 Interprofessional Education & Clinical Teaching Strategies 19.3 Developing Age-Appropriate Patient Educational Materials

20 Chapter 20: Pediatric Immunizations & Public Health Advocacy

20.1 ACIP Pediatric Immunization Schedule: Routine Childhood Vaccines 20.2 Adolescent Immunizations, Vaccine Hesitancy & Catch-Up Schedules 20.3 Pediatric Public Health Disparities & Special Population Advocacy

21 Chapter 21: Pediatric Practice Management — Laboratory Stewardship, Pharmacoeconomics & Informatics

21.1 Pediatric Laboratory Practices: Blood Conservation, Sampling Timing & Age-Specific Reference Intervals 21.2 Pharmacoeconomics, Formulary Management & Cost-Containment in Pediatrics 21.3 Clinical Informatics, CPOE Decision Support & Drug Shortage Management

9.1 PALS Resuscitation Algorithms & Cardiac Arrest Pharmacotherapy

Key Takeaways Explain This Topic AI

High-quality CPR is the cornerstone of pediatric resuscitation: delivery of 100–120 chest compressions/min to a depth of at least one-third the anterior-posterior diameter of the chest (~4 cm [1.5 inches] in infants, ~5 cm [2 inches] in children) with full chest recoil and a 15:2 compression-to-ventilation ratio for two healthcare rescuers without an advanced airway.

Shockable rhythms (VF / pulseless VT) mandate immediate unsynchronized defibrillation: 2 J/kg for the initial shock, 4 J/kg for the second shock, and ≥4 J/kg (up to 10 J/kg or adult maximum of 200 J biphasic) for subsequent shocks, integrated with uninterrupted CPR cycles.

Epinephrine is the primary vasopressor for cardiac arrest: administered at 0.01 mg/kg (0.1 mL/kg of the 0.1 mg/mL [1:10,000] concentration; maximum single dose 1 mg) IV/IO every 3–5 minutes; in non-shockable arrest (asystole/PEA), administer immediately within the first minutes of resuscitation.

Refractory VF/pVT persisting beyond the second shock requires antiarrhythmic administration: amiodarone 5 mg/kg IV/IO bolus (maximum single dose 300 mg, repeatable up to 2 times for a cumulative maximum of 15 mg/kg) or lidocaine 1 mg/kg IV/IO loading dose followed by a continuous maintenance infusion of 20–50 mcg/kg/min.

Endotracheal (ET) drug administration (LEAN/NAVEL) is strictly a last resort due to erratic alveolar absorption; the ET epinephrine dose is 0.1 mg/kg (0.1 mL/kg of the 1 mg/mL [1:1,000] concentration), representing a 10-fold increase over the IV/IO dose, followed by a 5 mL normal saline flush.

Last updated: September 2026

9.1 PALS Resuscitation Algorithms & Cardiac Arrest Pharmacotherapy

Pediatric cardiopulmonary arrest is physiologically distinct from adult sudden cardiac arrest. While adult cardiac arrest is predominantly secondary to primary ischemic ventricular dysrhythmias, pediatric arrest is overwhelmingly the terminal consequence of progressive tissue hypoxia and respiratory failure or uncompensated circulatory shock. Over 70% to 80% of pediatric arrests present initially with non-shockable rhythms—specifically asystole or pulseless electrical activity (PEA). Consequently, successful resuscitation depends on the immediate restoration of oxygen delivery, high-quality chest compressions, early vasopressor administration, and systematic identification of reversible underlying causes.

High-Quality CPR & Resuscitation Metrics

Cardiopulmonary resuscitation (CPR) must be initiated immediately upon recognizing cardiac arrest (unresponsiveness, absent breathing or only gasping, and no central pulse detected within 10 seconds). The quality of CPR directly dictates coronary perfusion pressure (CPP) and cerebral blood flow.

Essential CPR Quality Benchmarks

Compression Rate: 100 to 120 compressions per minute.

Compression Depth: At least one-third the anterior-posterior (AP) diameter of the chest:

Infants (<1 year): Approximately 1.5 inches (4 cm).

Children (1 year to puberty): Approximately 2 inches (5 cm).

Adolescents: 2 to 2.4 inches (5 to 6 cm).

Chest Recoil: Allow complete chest wall recoil between compressions; leaning on the chest elevates intrathoracic pressure, blunts venous return, and severely reduces coronary perfusion pressure.

Compression-to-Ventilation Ratio:

Single Rescuer: 30:2 compressions-to-ventilations.

Two Healthcare Rescuers: 15:2 compressions-to-ventilations.

With Advanced Airway (ETT / Supraglottic): Continuous chest compressions without pauses for ventilations; deliver 1 breath every 2 to 3 seconds (20 to 30 breaths/min) .

Minimize Interruptions: Keep pauses in compressions to <10 seconds (e.g., during rhythm analysis and defibrillation charging).

Avoid Hyperventilation: Excessive ventilation increases intrathoracic pressure, compresses the vena cava and pulmonary vascular bed, decreases cardiac output, and induces cerebral vasoconstriction via acute hypocapnia ( P a C O 2 < 35 mmHg PaCO_2 < 35 \text{ mmHg} P a C O 2 ​ < 35 mmHg ).

Shockable Rhythms: VF & Pulseless VT Algorithm

Ventricular fibrillation (VF) and pulseless ventricular tachycardia (pVT) represent approximately 15% to 20% of pediatric in-hospital cardiac arrests (and up to 25% of sudden out-of-hospital collapses in older children and adolescents). The primary therapeutic intervention is rapid, unsynchronized electrical defibrillation. Shockable Cardiac Arrest Flow (VF / Pulseless VT):

  • [Recognize VF/pVT] ──► [Shock 1: 2 J/kg] ──► [Immediate CPR x 2 min]
  • │
  • [Rhythm Check: Persistent VF/pVT]
  • │
  • ▼
  • [Shock 2: 4 J/kg]
  • │
  • ▼
  • [Immediate CPR x 2 min]
  • Epinephrine 0.01 mg/kg IV/IO
  • Repeat Epinephrine q3-5 min
  • │
  • [Rhythm Check: Persistent VF/pVT]
  • │
  • ▼
  • [Shock 3: >=4 J/kg (max 10 J/kg)]
  • │
  • ▼
  • [Immediate CPR x 2 min]
  • Amiodarone 5 mg/kg IV/IO
  • OR Lidocaine 1 mg/kg IV/IO
  • Defibrillation Dosing Sequence

First Shock: 2 J/kg (biphasic or monophasic).

Second Shock: 4 J/kg .

Subsequent Shocks: ≥ 4 J/kg \ge 4 \text{ J/kg} ≥ 4 J/kg (titrated up to 10 J/kg or the adult maximum biphasic dose of 200 J [or 360 J monophasic]).

Critical Rule: Immediately resume high-quality CPR for 2 minutes following every shock without pausing to check rhythm or pulse.

Resuscitation Pharmacotherapy for Shockable Arrest

Epinephrine:

Timing: Administer during CPR following the second shock (Cycle 2).

Dose: 0.01 mg/kg IV/IO ( 0.1 mL/kg of 0.1 mg/mL [1:10,000] solution; maximum single dose: 1 mg / 10 mL ).

Frequency: Repeat every 3 to 5 minutes throughout the arrest.

Antiarrhythmic Selection (Refractory VF/pVT):

Indicated for persistent VF or pulseless VT refractory to CPR, defibrillation, and vasopressor therapy (administered after the third shock ).

Amiodarone:

Dose: 5 mg/kg IV/IO rapid bolus (maximum single dose: 300 mg ).

Repetition: May repeat the 5 mg/kg bolus twice for refractory VF/pVT (cumulative maximum dose: 15 mg/kg or 450 mg per 24 hours).

Formulation Note: Amiodarone contains polysorbate 80 and benzyl alcohol, which cause peripheral vasodilation and myocardial depression in perfusing rhythms; however, in pulseless cardiac arrest, it is administered as a rapid IV/IO push.

Lidocaine:

Loading Dose: 1 mg/kg IV/IO bolus (maximum: 100 mg ).

Maintenance Infusion: If ROSC is achieved, initiate a continuous infusion at 20 to 50 mcg/kg/min (0.02 to 0.05 mg/kg/min) to prevent recurrence of malignant ventricular arrhythmias.

Clinical Evidence: The ROC-ALPS and multicenter pediatric resuscitation studies demonstrated equivalent rates of ROSC and survival to hospital discharge between amiodarone and lidocaine. Lidocaine is frequently preferred due to easier preparation and fewer drug-drug interactions.

Non-Shockable Rhythms: Asystole & PEA Algorithm

Pulseless electrical activity (PEA) and asystole constitute the vast majority of pediatric cardiac arrests. Because electrical defibrillation has no efficacy in non-shockable rhythms, survival depends entirely on uninterrupted CPR, rapid vasopressor administration, and identifying the underlying trigger .

Immediate Priorities

Initiate High-Quality CPR: Provide continuous chest compressions and ventilations with 100% oxygen.

Immediate Epinephrine Administration:

In non-shockable rhythms, epinephrine must be administered as soon as vascular access (IV or IO) is obtained .

Dosing: 0.01 mg/kg IV/IO ( 0.1 mL/kg of 0.1 mg/mL [1:10,000] ; maximum single dose: 1 mg ), repeated every 3 to 5 minutes .

Time-to-Epinephrine Criticality: Large observational pediatric cohorts confirm that every 1-minute delay in epinephrine administration beyond 5 minutes from arrest onset leads to a step-wise decline in ROSC, survival to discharge, and favorable neurological outcome.

Search for Reversible Etiologies: Actively investigate and correct reversible causes throughout the resuscitation.

Vascular Access & Routes of Drug Delivery

Route Priority Pharmacokinetic Considerations & Dosing Rules

Intravenous (IV) First-Line Peripheral or central. Flush all peripheral medications with 5 to 10 mL of 0.9% NaCl to ensure drug reaches central circulation during CPR.

Intraosseous (IO) First-Line (Rapid) Establish if IV access is not secured within 1–2 minutes. Preferred sites: proximal tibia (1–2 cm distal and medial to tibial tuberosity), distal femur, or proximal humerus. Sternal IO is contraindicated in young children due to risk of mediastinal and cardiac injury. Flow rates and drug pharmacokinetics equal IV delivery. Flush with 5–10 mL NS.

Endotracheal (ET) Last Resort Only Used strictly when IV/IO access cannot be obtained. Limited to lipid-soluble drugs ( LEAN / NAVEL : Lidocaine, Epinephrine, Atropine, Naloxone). Absorption is highly erratic, delayed, and unpredictable due to severe pulmonary ventilation-perfusion mismatch during CPR.

Endotracheal Drug Dosing Mandates

Epinephrine ET Dose: 0.1 mg/kg ( 0.1 mL/kg of the concentrated 1 mg/mL [1:1,000] formulation).

The 10-Fold Rule: The endotracheal dose of epinephrine is 10 times higher than the standard IV/IO dose ( 0.1 mg/kg 0.1 \text{ mg/kg} 0.1 mg/kg vs 0.01 mg/kg 0.01 \text{ mg/kg} 0.01 mg/kg ).

Technique: Dilute in 1 to 5 mL of 0.9% normal saline, instill directly into the endotracheal tube (past the tip using a catheter), and follow with 5 rapid positive-pressure ventilations to disperse the medication into the distal alveolar bed.

Contraindicated ET Drugs: Sodium bicarbonate and calcium salts must NEVER be administered via the endotracheal tube ; they cause acute chemical alveolitis, mucosal sloughing, and surfactant deactivation.

Reversible Causes of Pediatric Arrest: The H's and T's Reversible Causes (H's & T's) Differential Matrix:

  • [Hypovolemia] ──► 20 mL/kg balanced crystalloid / blood
  • [Hypoxia] ──► 100% FiO2, bag-mask / endotracheal intubation
  • [Hydrogen Ion (Acid)]──► Sodium bicarbonate 1 mEq/kg (if documented)
  • H's [Hypoglycemia] ──► D10W 5-10 mL/kg (neonates/infants) or D25W 2-4 mL/kg
  • [Hypo/Hyperkalemia] ──► Ca-gluconate/chloride, insulin+dextrose, albuterol
  • [Hypothermia] ──► Active internal/external rewarming
  • [Tension Pneumothorax] ──► Needle thoracostomy (2nd ICS MCL or 4th/5th AAL)
  • [Tamponade (Cardiac)] ──► Emergent pericardiocentesis
  • T's [Toxins / Overdose] ──► Naloxone, lipid emulsion, specific antidotes
  • [Thrombosis (Pulm/PE)] ──► Thrombolytics (Alteplase 0.1-0.6 mg/kg) / ECMO
  • [Thrombosis (Coronary)]──► Percutaneous intervention / anticoagulation

Etiology Clinical Suspicion Immediate Pharmacotherapy / Intervention

Hypovolemia Dehydration, trauma, hemorrhage, sepsis 20 mL/kg balanced crystalloid (LR or Plasma-Lyte) rapid push; if hemorrhagic, administer 10 mL/kg PRBCs or massive transfusion protocol (1:1:1 PRBC, FFP, platelets).

Hypoxia Airway obstruction, respiratory distress, drowning Deliver 100% F i O 2 FiO_2 F i O 2 ​ ; verify ETT position; suction airway; correct ventilation failure.

Hydrogen Ion (Acidosis) Prolonged arrest, DKA, inborn errors of metabolism Sodium bicarbonate: 1 mEq/kg IV/IO slow push ( 1 mL/kg of 8.4% solution in children ≥ 2 \ge 2 ≥ 2 years; dilute 1:1 with sterile water to 4.2% in neonates/infants to prevent hyperosmolar intraventricular hemorrhage). Indicated only for documented severe metabolic acidosis, hyperkalemia, or tricyclic antidepressant toxicity.

Hypoglycemia Neonates, septic shock, adrenal insufficiency Check point-of-care glucose immediately. Dextrose dose: 0.5 to 1 g/kg IV/IO:; • Infants/Neonates: D10W 5 to 10 mL/kg .; • Children >1 year: D25W 2 to 4 mL/kg .; (Avoid D50W in young children due to severe hyperosmolality and sclerosis).

Hyperkalemia Renal failure, tumor lysis syndrome, crush injury 1. Membrane Stabilization: Calcium chloride 10% 20 mg/kg ( 0.2 mL/kg 0.2 \text{ mL/kg} 0.2 mL/kg , max 1,000 mg) via central line, OR Calcium gluconate 10% 60 mg/kg ( 0.6 mL/kg 0.6 \text{ mL/kg} 0.6 mL/kg , max 3,000 mg) via peripheral/central line.; 2. Intracellular Shift: Regular insulin 0.1 unit/kg IV with D25W 2 mL/kg (0.5 g/kg) + continuous nebulized albuterol.; 3. Elimination: Sodium zirconium cyclosilicate or emergent dialysis.

Tension Pneumothorax Asymmetric breath sounds, tracheal deviation, distended neck veins Immediate needle thoracostomy (14–18 gauge angiocatheter in 2nd intercostal space midclavicular line or 4th/5th intercostal space anterior axillary line), followed by tube thoracostomy.

Cardiac Tamponade Muffled heart tones, narrow pulse pressure, pericardial effusion Emergent ultrasound-guided pericardiocentesis ; volume expansion as temporizing measure.

Toxins / Poisoning Suspected ingestion, miosis/mydriasis, arrhythmias • Opioids: Naloxone 0.1 mg/kg IV/IO/IM (max 2 mg).; • Local Anesthetic Systemic Toxicity (LAST): 20% Lipid Emulsion 1.5 mL/kg bolus, then 0.25 mL/kg/min .; • Beta-blockers: Glucagon 50 to 100 mcg/kg IV (max 10 mg) + High-Dose Insulin Euglycemia Therapy (HIET; 1 unit/kg bolus + 0.5–1 unit/kg/h with dextrose).

Post-Resuscitation Care & Targeted Temperature Management (TTM)

Following Return of Spontaneous Circulation (ROSC), patients enter the post-cardiac arrest syndrome phase, characterized by brain injury, myocardial dysfunction, systemic ischemia-reperfusion response, and persistent precipitating pathology.

Targeted Temperature Management (TTM) Protocols

Brain injury is the leading cause of mortality and long-term morbidity after pediatric cardiac arrest. Post-ROSC fever markedly increases cerebral metabolic rate ( C M R O 2 CMRO_2 CMR O 2 ​ ) by approximately 6% to 8% per 1 ∘ C 1^\circ\text{C} 1 ∘ C rise, uncoupling oxygen supply and demand, promoting free radical release, and exacerbating neuronal apoptosis.

Target Temperature Range:

Induced Therapeutic Hypothermia: Maintain core temperature between 32 ∘ C 32^\circ\text{C} 3 2 ∘ C and 34 ∘ C 34^\circ\text{C} 3 4 ∘ C for 48 hours, followed by controlled slow rewarming at a rate of 0.25 ∘ C 0.25^\circ\text{C} 0.2 5 ∘ C to 0.5 ∘ C 0.5^\circ\text{C} 0. 5 ∘ C per hour .

Actively Controlled Normothermia: Maintain core temperature between 36 ∘ C 36^\circ\text{C} 3 6 ∘ C and 37.5 ∘ C 37.5^\circ\text{C} 37. 5 ∘ C for 72 hours.

The THAPCA Trials (Therapeutic Hypothermia After Pediatric Cardiac Arrest): Randomized multi-center clinical trials in both in-hospital (THAPCA-IH) and out-of-hospital (THAPCA-OH) pediatric cardiac arrest demonstrated equivalent 1-year survival with favorable neurobehavioral outcomes between hypothermia (32–34°C) and controlled normothermia (36–37.5°C).

BCPPS Clinical Rule: Both hypothermia (32–34°C) and normothermia (36–37.5°C) are acceptable guidelines-endorsed options; however, active prevention and aggressive treatment of fever ( T ≥ 38 ∘ C T \ge 38^\circ\text{C} T ≥ 3 8 ∘ C ) is universally mandatory .

Hemodynamic, Respiratory & Neurological Goals Post-ROSC

Blood Pressure Optimization: Maintain systolic and mean arterial pressure (MAP) at least above the 50th percentile for age (or > 5 th >5\text{th} > 5 th percentile threshold at minimum) using continuous vasoactive infusions (epinephrine or norepinephrine) to ensure adequate cerebral perfusion pressure ( C P P = M A P − I C P CPP = MAP - ICP CPP = M A P − I CP ).

Oxygenation Strategy: Titrate inspired oxygen ( F i O 2 FiO_2 F i O 2 ​ ) to maintain oxyhemoglobin saturation between 94% and 99% . Strictly avoid hyperoxia ( P a O 2 > 300 mmHg PaO_2 > 300 \text{ mmHg} P a O 2 ​ > 300 mmHg ), which accelerates reactive oxygen species (ROS) formation and reperfusion tissue injury. Avoid hypoxia ( S p O 2 < 94 % SpO_2 < 94\% Sp O 2 ​ < 94% ).

Ventilation Strategy: Target normocapnia ( P a C O 2 35 to 45 mmHg PaCO_2 \text{ 35 to 45 mmHg} P a C O 2 ​ 35 to 45 mmHg ). Prevent hypocapnia ( P a C O 2 < 35 mmHg PaCO_2 < 35 \text{ mmHg} P a C O 2 ​ < 35 mmHg ), which triggers cerebral vasoconstriction and worsens ischemic brain injury. Prevent severe hypercapnia, which increases intracranial pressure ( I C P ICP I CP ).

Glucose Control: Target blood glucose 80 to 180 mg/dL . Prevent hypoglycemia (exacerbates brain death) and treat severe hyperglycemia with titrated regular insulin infusions.

Electroencephalography (EEG): Continuous EEG monitoring is recommended for at least 24 to 48 hours post-ROSC; non-convulsive status epilepticus occurs in 10% to 40% of comatose pediatric survivors and requires aggressive anticonvulsant management (levetiracetam, fosphenytoin, midazolam infusions).